scholarly journals Management of dysfunctional uterine bleeding based on endometrial thickness

2010 ◽  
pp. 297 ◽  
Author(s):  
Ozgul Muneyyirci-Delale
Keyword(s):  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding

scholarly journals Ormeloxifene versus combined oral contraceptive pills to control blood loss in cases of dysfunctional uterine bleeding

2019 ◽  
Vol 8 (12) ◽  
pp. 4909
Author(s):  
Ankita Gupta ◽  
Rishika Raj
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Menstrual Blood ◽  
Control Group ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

Background: Dysfunctional uterine bleeding is one of the most often encountered gynecologic problems causing anemia, reduced quality of life and unnecessary hysterectomies. A prospective study was conducted on women with DUB to study the effect of ormeloxifene versus combined oral contraceptive pills in controlling blood loss in them.Methods: 100 Women with DUB were enrolled randomly in three groups. After baseline assessment each patient in group A was treated with iron tablets, containing 100 mg elemental iron and folic acid 1.5 mg, for three months and were termed as control group. Group B patients were treated with ormeloxifene in dose of 60 mg twice a week for twelve weeks. Group C patients were treated with combined oral contraceptive pills for twenty- one days starting from third day of their LMP. The treatment was continued for three consecutive cycles. The efficacy of the studied drugs was analyzed by comparing the baseline and post treatment PBAC score, haemoglobin level and endometrial thickness, using appropriate statistical tests.Results: Ormeloxifene was more effective than only iron or combined oral contraceptive therapy in controlling menstrual blood loss (79.11% versus 58.57%). There was a reduction in endometrial thickness in group receiving ormeloxifene as well as in the group receiving combined oral contraceptive pills (p=0.486), however this was statistically not significant.Conclusions: Ormeloxifene was significantly better than combined OCP in reduction of menstrual blood flow in cases of DUB. It has better compliance and marked improvement in subjective symptoms as compared to OCP.

scholarly journals Dysfunction of the Clinical Effect of Levonorgestrel Treatment of Dysfunctional Uterine Bleeding

2013 ◽  
Vol 2 ◽  
pp. 4
Author(s):  
Xinhui Mi ◽  
Caixia Qin
Keyword(s):  
Adverse Reaction ◽  
Clinical Practice ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Endometrial Thickness ◽  
Hemoglobin Concentration ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
Curative Effect ◽  
Intrauterine Treatment

<strong>Objective: </strong>Study clinical curative effect of levonorgestrel treatment on perimenopausal dysfunctional uterine bleeding. Method: Selected 126 outpatient of dysfunctional uterine bleeding which hospitalize from December 2010 to December 2012 at department of gynaecology to undergo levonorgestrel treatment on the 5‒7 days of menstruation. The endometrial thickness, hemoglobin, and the PBAC score of before and 3, 6, and 12 months after placement were observed and recorded. To observation the adverse reactions after levonorgestrel treatment. <strong>Results: </strong>After treatment, the thickness of the endometrium, the amount of menstruation and the hemoglobin concentration increased in 126 patients. During the treatment, 21 patients experienced mild dizziness and nausea, but did not affect the drug use and efficacy. <strong>Conclusion: </strong>Effects of levonorgestrel on intrauterine treatment of perimenopausal dysfunctional uterine bleeding can effectively reduce the amount of menstruation and increase hemoglobin levels. It is economic, simple, less adverse reaction, and widely entrenched in clinical practice.

scholarly journals Comparison between Ormeloxifene and Norethisterone in reducing menorrhagia in dysfunctional uterine bleeding

2018 ◽  
Vol 7 (12) ◽  
pp. 4966
Author(s):  
Swati Gett ◽  
Shruti Singh
Keyword(s):  
Endometrial Thickness ◽  
Mean Value ◽  
Uterine Bleeding ◽  
The Other ◽  
P Value ◽  
Loss Assessment ◽  
Dysfunctional Uterine Bleeding ◽  
Significant Difference ◽  
Before And After

Background: Dysfunctional Uterine Bleeding (DUB) is a condition that affects nearly every woman at some point in her life. This study aims to compare the efficacy of Ormeloxifene and Norethisterone in reducing menorrhagia in such patients.Methods: This prospective study was done on 100 women presenting with dysfunctional uterine bleeding, of 20-50 years of age, who were ready for follow-up and were allocated into two equal groups, one was given Ormeloxifene and the other was given Norethisterone for a period of 3 months. Haemoglobin levels, endometrial thickness on ultrasound and Pictorial Blood loss Assessment Chart (PBAC) scores were assessed before and after the treatment.Results: It was found that both Ormeloxifene and Norethisterone reduced menorrhagia, with a significant difference in PBAC scores (p value <0.05). There was a notable reduction in PBAC scores in Ormeloxifene group (66.53% change from pretreatment mean value) as compared to Norethisterone group (31.38% change from pretreatment mean value); and same holds true for the change in haemoglobin levels as well as endometrial thickness. Ormeloxifene was found to have a greater effect on heavy menstrual bleeding in comparison to Norethisterone.Conclusions: Ormeloxifene is a new modality and is found to be a better option in reducing menorrhagia in DUB in respect to a greater success rate, better compliance and cost effectiveness.

scholarly journals The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding

2016 ◽  
Vol 6 (1) ◽  
pp. 219 ◽  
Author(s):  
Nikita Gandotra ◽  
Preeti Sharma ◽  
Abhinav Sharma ◽  
Syed Masuma Rizvi
Keyword(s):  
Side Effects ◽  
Outcome Measures ◽  
Medical Management ◽  
Endometrial Thickness ◽  
Hemoglobin Concentration ◽  
Uterine Bleeding ◽  
Secondary Outcome ◽  
Dysfunctional Uterine Bleeding ◽  
The Mean

Background: Dysfunctional uterine bleeding (DUB) is a common gynaecological disorder that usually ends up in hysterectomy and causes psychological and physiological stress. Medical management with hormones and NSAIDS has inherited side effects. Ormeloxifene, a selective estrogen receptor modulator, is emerging as a safe and effective agent for dysfunctional uterine bleeding. The objective of the study was to evaluate the role of ormeloxifene in medical management of dysfunctional uterine bleeding.Methods: 30 patients, on whom diagnosis of dysfunctional uterine bleeding was made, were included in the study. Patients were given ormeloxifene 60mg twice a week for 12 weeks and then once a week for 12 weeks. The primary outcome measures were menstrual blood loss (assessed by pictorial blood assessment chart score), hemoglobin concentration and endometrial thickness. The secondary outcome measures were acceptability and side effects of ormeloxifene.Results: There was a significant reduction in mean PBAC score from 316 to 52 after six months of treatment. The mean hemoglobin concentration increased significantly from 8.4 to 9.8 gms/dl with a rise of 1.4gm/dl (p <0.05). The mean pretreatment endometrial thickness was 10.8mm and it decreased significantly to 8.1mm after 6 months of treatment with ormeloxifene (p < 0.05). 76.7% of the women showed marked subjective improvement in symptoms. The most common side effect reported was amenorrhea (13.3%).Conclusions: Ormeloxifene can be considered as an effective and safe therapeutic option for the medical management of dysfunctional uterine bleeding.

scholarly journals Targeted treatments for dysfunctional uterine bleeding based on endometrial thickness

2020 ◽  
Vol 9 (3) ◽  
pp. 900
Author(s):  
Thi Thi Htwe ◽  
Hla Hla Yi ◽  
Saw Kler Ku
Keyword(s):  
Endometrial Thickness ◽  
Hormonal Treatment ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
Common Presentation ◽  
Targeted Treatments ◽  
One Year ◽  
The One

Background: Dysfunctional uterine bleeding is a common presentation to both general practitioner and gynaecologists which can have a significant effect on a woman’s quality of life. The aim of this study is to assess the effectiveness of treating dysfunctional uterine bleeding according to endometrial thickness.Methods: This study was a hospital based prospective study undertaken in gynecology outpatient clinic of Central Women’s Hospital, Mandalay, Myanmar for one-year period (2016). A total of 60 patients were recruited and divided into 3 groups based on endometrial thickness and offered targeted hormonal treatments. At the end of the one-month treatment, patients were asked to return for a follow-up visit and from their menstrual diaries, the number of bleeding days and bleeding scores were assessed and calculated.Results: Among sixty women with dysfunctional uterine bleeding, 55% of patients had endometrial thickness less than 6 mm, 25% had endometrial thickness 6-11 mm, with 20% of patients having endometrial thickness more than 11 mm. After one month of study period, treatment was found to be effective in 86.6% of the patients according to bleeding days and in 70% of the patients according to bleeding score.Conclusions: In women presenting with dysfunctional uterine bleeding, increased endometrial thickness was found to be associated with increased BMI. In the treatment of dysfunctional uterine bleeding, when the endometrial thickness of the patient was assessed and hormonal treatment was given according to the endometrial thickness, treatment was proven to be effective.

scholarly journals Efficacy and safety of ormeloxifene in the management of dysfunctional uterine bleeding

2019 ◽  
Vol 8 (5) ◽  
pp. 1864
Author(s):  
Sabah Malik ◽  
Saba Musharaf ◽  
Fidah Malik ◽  
Mohd Abass
Keyword(s):  
Blood Loss ◽  
Endometrial Thickness ◽  
Abnormal Uterine Bleeding ◽  
Uterine Bleeding ◽  
Menstrual Blood ◽  
Prospective Clinical Study ◽  
Efficacy And Safety ◽  
Menstrual Blood Loss ◽  
Dysfunctional Uterine Bleeding ◽  
The Mean

Background: The term dysfunctional uterine bleeding (DUB) is used for abnormal uterine bleeding occurring in the absence of identifiable pathology. A number of drugs are available for management of DUB- nonsteroidal anti-inflammatory drugs, tranexamic acid, ethamsylate, hormones like Oral contraceptives progestins etc. The present study was done to determine the efficacy and safety of ormeloxifene in the management of DUB.Methods: This prospective clinical study involved 50 cases with DUB who were treated with ormeloxifene 60 mg tablet twice a week for first 12 weeks and the once a week for next 12 weeks. They were followed after 6 months of therapy. The outcome was studied by assessment of menstrual blood loss by PBAC score, Hb level in g/dl, endometrial thickness in mm, relief of dysmenorrheal and any side effects of drugs.Results: The median PBAC score was significantly reduced from 316 to 52 after 6 months of therapy. The mean Hb concentration was significantly increased from 7.8 g/dl to 9.1 g/dl at 6 months of therapy. The mean endometrial thickness was reduced from 10 mm to 7.9 mm after 6 months of therapy. 66% of women showed marked subjective improvement in symptoms. Amenorrhea was the main side effect (12%).Conclusions: Ormeloxifene has significant effect in reducing endometrial thickness, decreasing the amount of menstrual blood loss, reducing dysmenorrhea and thereby improving the general condition of the patient. It is definitely a better alternative to hysterectomy in women who wish to avoid surgeries and maintain their reproductive functions.

scholarly journals Ormeloxifene versus Tranexamic acid in dysfunctional uterine bleeding comparative evaluation

2018 ◽  
Vol 7 (2) ◽  
pp. 566
Author(s):  
Kaliki Hymavathi ◽  
Malini Devi Gottipati ◽  
Prasuna . ◽  
Sudha V.
Keyword(s):  
Tranexamic Acid ◽  
Endometrial Thickness ◽  
Hemoglobin Concentration ◽  
Abnormal Uterine Bleeding ◽  
Uterine Bleeding ◽  
Double Blind Study ◽  
Loss Assessment ◽  
Dysfunctional Uterine Bleeding ◽  
Double Blind ◽  
Beneficial Effects

Background: Dysfunctional Uterine bleeding (DUB) is the most common cause of abnormal uterine bleeding (AUB). Medical therapy being the first line of management, an ideal drug should be able to block the estrogenic effects on the Endometrium without interfering with its beneficial effects on other tissues. Both Ormeloxifene - a selective estrogen receptor modulator (SERM) and Tranexamic acid-an anti fibrinolytic inhibitor is important in the treatment of DUB. The aim of this study is to assess the efficacy and safety of Ormeloxifene v/s Tranexamic acid in the treatment of DUB.Methods: This is a prospective double blind study conducted for 2 years in 200 women presenting with DUB attending to the Gynaecology outpatient department (OPD) of Narayana Medical College and Hospital, Nellore, AP, India. Two hundred women presenting with DUB were recruited into this study (after fulfilling inclusion and exclusion criteria) with informed consent and randomly divided into two equal groups (Group-A and Group-B) after obtaining college ethical committee approval.Results: The reduction in the mean pictorial blood loss assessment chart (PBAC) score with Ormeloxifene (from 278 to 97.6) was significantly more than that of Tranexamic acid (from 261 to 134.5) at six months (p <0.0001). The rise in Hemoglobin concentration (8.4g% to 11.15g% vs. 8.5 to 9.7gm%; p <0.008) and reduction in Endometrial thickness (from 10.57mm to 6.5mm v/s 9.96mm to 7.24mm p <0.0001) were also significantly more with Ormeloxifene than with Tranexamic acid. Relief from dysmenorrhoea and subjective improvement were also found to be considerable with Ormeloxifene.Conclusions: Both Ormeloxifene and Tranexamic acid can be considered for DUB treatment but Ormeloxifene is found to be superior to Tranexamic acid in various aspects.

scholarly journals Dysfunctional uterine bleeding: ormeloxifene versus combined oral contraceptive pills

2018 ◽  
Vol 7 (9) ◽  
pp. 3610
Author(s):  
Sonia Luthra ◽  
A. D. Dwivedi
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills ◽  
Group A ◽  
Group B

Background: Dysfunctional uterine bleeding is abnormal bleeding that occurs in the absence of recognizable pelvic pathology, general medical disease, or pregnancy.  Globally, health care systems are focusing on low morbidity and low cost therapeutic interventions. Hence, medical treatment for DUB is high on the priority list. This comparative study was conducted to analyse the efficacy of ormeloxifene and combined oral contraceptive pills in reducing the blood loss and endometrial thickness in cases of DUB.Methods: This prospective study was conducted on women with dysfunctional uterine bleeding, who attended Gynaecology OPD at Hind Institute of Medical Sciences, between August 2015 and April 2016. After applying inclusion and exclusion criteria, 72 women diagnosed with DUB were enrolled randomly in two groups A and B. Group A was treated by Ormeloxifene and Group B patients were treated with combined oral contraceptive pills for three consecutive cycles. The efficacies of the studied drugs were compared by analyzing the mean change in the pre and post treatment PBAC score, haemoglobin level and endometrial thickness using unpaired t-test.Results: Ormeloxifene was found to be significantly more effective (p <0.0001) than OCPs in controlling the menstrual blood loss (79% reduction in group A Vs 55.5% reduction in group B). Reduction in endometrial thickness was also more in the group receiving Ormrloxifene, however this was statistically not significant (p = 0.19). No major side effect observed with the use of Ormeloxifene.Conclusions: Ormeloxifene can be an effective and safe therapy in the treatment of Dysfunctional uterine bleeding.

Sign in / Sign up

Export Citation Format

Share Document